Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients  

作　　者：Guang-sheng He Xiang Zhang De-pei Wu Ai-ning Sun Zheng-ming Jin Hui-ying Qiu Miao Miao Xiao-wen Tang Zheng-zheng Fu Yue Han 

机构地区：[1]Jiangsu Insititute of Hematology, the First Affiliated Hospital of Soochow University, Thrombosis and Hemostasis Key Laboratory of Ministry of Health of Soochow University, Suzhou 215006, China

出　　处：《Chinese Medical Sciences Journal》2009年第3期178-181,共4页中国医学科学杂志（英文版）

基　　金：Supported by the Development of Society Foundation of Suzhou (SS0813);the Natural Science Foundation of Jiangsu Province (2004BK424);the 135 Key Department Foundation of Jiangsu Province (135XY0416);the Outstanding Person Fund the Jiangsu Province (LJ200626);the Outstanding Person Fund of the First Affiliated Hospital of Soochow University (2004YQG05)

摘　　要：Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor （CAG） regimen for refractory biphenotypic acute leukemia （BAL）. Methods We treated 5 refractory BAL patients by CAG regimen （10 mg.m 2 cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg·m^-2 aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 μg·m^-2·d^-1 granulocyte colony-stimulating factor subcutaneously） from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured. Results The complete remission rate was 80%, median duration of absolute neutrophil count〈5.0×10^8/L and platelet count〈2.0×10^10/L was day 13 and day 1, respectively; and the infection rate was low （Ⅲ-Ⅳ infection rate, 20.00%）.

关 键 词：acute leukemia biphenotype cytosine arabinoside granulocyte colony-stimulating factor 

分 类 号：S859.795[农业科学—临床兽医学] Q344.13[农业科学—兽医学]